Shortly after the onset of the COVID-19 pandemic, severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has acquired numerous variations in its intracellular proteins to …

The SARS-CoV-2 main protease (Mpro) is the drug target of Pfizer's oral drug nirmatrelvir.
The emergence of SARS-CoV-2 variants with mutations in Mpro raised the alarm of potential …

SARS-CoV-2 continues to pose a threat to public health. Main protease (Mpro) is one of the
most lucrative drug targets for developing specific antivirals against SARS-CoV-2 infection …

SARS-CoV-2 is the causative agent of COVID-19. The main viral protease (M pro) is an
attractive target for antivirals. The clinically approved drug nirmatrelvir and the clinical …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to represent a
global health emergency as a highly transmissible, airborne virus. An important coronaviral …

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …

The COVID-19 pandemic continues to be a public health threat. Multiple mutations in the
spike protein of emerging variants of SARS-CoV-2 appear to impact on the effectiveness of …

Conspectus SARS-CoV-2 is the etiological pathogen of the COVID-19 pandemic, which led
to more than 6.5 million deaths since the beginning of the outbreak in December 2019. The …

Coronaviruses can evolve and spread rapidly to cause severe disease morbidity and
mortality, as exemplified by SARS-CoV-2 variants of the COVID-19 pandemic. Although …

Drugs that target the main protease (Mpro) of SARS-CoV-2 are effective therapeutics that
have entered clinical use. Wide-scale use of these drugs will apply selection pressure for the …